Cytochrome P450 2E1 participation in the pathogenesis of experimental metabolic syndrome in guinea pigs.

In this work the experimental metabolic syndrome on the basis of protamine sulfate modeling in guinea pigs was reproduced and pathological processes in the liver of experimental animals were studied. We determined the level of free radicals and markers of liver damage in the blood of experimental animals. We investigated the liver glycogen content and K+,Na+-ATPase activity in the liver of experimental animals as well as measured the cytochrome P450 2E1 (CY P2E1) expression – one of the main factors of oxidative stress.

[Insulin determination in pancreas of guinea pigs with metabolic syndrome].

The level of insulin production is one of the integral parameters during the modeling of metabolic syndrome in animals. Comparison of this parameter with blood glucose level can characterize the degree of insulin resistance of cells. In this work we determined the level of insulin in pancreatic cells of guinea pigs under normal conditions and during metabolic syndrome.

[Optimization of animal model for investigation of pathogenesis of type 2 diabetes].

Diabetes mellitus is one of the three most common modem diseases. A number of animal models is used in investigations of the mechanisms of development of the disease. Most of these models replicate the symptoms of type 1 diabetes mellitus.

[Antiproteolytic activity of the blood serum in adolescents with pulmonary tuberculosis].

The antiproteolytic activity of the blood serum was examined in the course of hospital treatment of 128 adolescents with prevailingly torpid forms of pulmonary tuberculosis and in 19 adolescents with tubercular infection (control). A direct correlation has been found between the degree of clinico-roentgenological manifestations of the disease and level of serum alpha 1-inhibitor of proteinases as well as between the efficacy of treatment and normalization of the antiproteolytic activity of the blood of the patients. It proposed to use the determination of alpha 1-inhibitor of proteinases as an additional criterion of evaluation of the clinical course and outcomes of the disease in adolescents.